Feature | October 31, 2013

Philips, RealView Conclude First Study to Evaluate Live 3-D Holographic Imaging in the Cath Lab

cath lab tct advanced visualization hybrid or philips realview holographic 3-D
October 31, 2013 — Philips and RealView Imaging Ltd. have completed a clinical study that demonstrated the feasibility of using an innovative live 3-D holographic visualization and interaction technology to guide minimally invasive structural heart disease procedures. In the pilot study that involved eight patients and was conducted in collaboration with the Schneider Children’s Medical Center in Petach Tikva, Israel, RealView’s visualization technology was used to display interactive, real-time 3-D holographic images acquired by Philips’ interventional X-ray and cardiac ultrasound systems.
 
In addition to viewing the patient’s heart on a 2-D screen, doctors in the interventional team were able to view detailed dynamic 3-D holographic images of the heart “floating in free space” during a minimally invasive structural heart disease procedure without using special eyewear. The doctors were also able to manipulate the projected 3-D heart structures by touching the holographic volumes in front of them. The study demonstrated the potential of the technology to enhance the context and guidance of structural heart repairs.
 
“The holographic projections enabled me to intuitively understand and interrogate the 3-D spatial anatomy of the patient’s heart, as well as to navigate and appreciate the device-tissue interaction during the procedure,” said Dr. Einat Birk, pediatric cardiologist and director, Institute of Pediatric Cardiology, Schneider Children’s Medical Center.
 
“The ability to reach into the image and apply markings on the soft tissue anatomy in the X-ray and 3-D ultrasound images would be extremely useful for guidance of these complex procedures,” said Dr. Elchanan Bruckheimer, pediatric cardiologist and director, cardiac catheterization laboratories, Schneider Children’s Medical Center.
 
Bruckheimer presented the results of the pilot study at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
“Our ultimate goal is to create the future of healthcare by delivering innovative solutions that enhance clinical capabilities and improve patient outcomes,” said Bert van Meurs, general manager, Integrated Clinical Solutions and Marketing Imaging Systems, Philips Healthcare. “By teaming up with partners that share our passion for innovation, we have been able to demonstrate the feasibility and potential value of the world’s first holographic visualization technology targeted at guiding minimally invasive cardiac procedures.”
 
“I see clear indications that 3-D medical holography will play an important role in medical imaging in the near future,” said Aviad Kaufman, CEO, RealView. “With the advancement of live 3-D imaging and increasing clinical evidence of its value for a variety of procedures, we are convinced that our holographic technology will further enhance 3-D imaging and, most importantly, improve patient care.”
 
Progress in image-guided therapies for heart diseases — from the opening of obstructed coronary arteries to catheter ablation therapy for heart arrhythmias and catheter-based structural heart repairs (for example, heart valve replacements) — have greatly increased the need for live 3-D image guidance to supplement today’s live 2-D image guidance. Live X-ray and live 3-D cardiac ultrasound imaging are typically used simultaneously to guide minimally invasive structural heart repair procedures, with the ultrasound images providing detailed insights into the heart’s soft tissue anatomy and the X-ray imaging providing visualization of catheters and heart implants.
 
The technological advancements in the acquisition of live 3-D images to guide minimally invasive procedures have also triggered the development of novel ways to visualize the data. Following the promising results produced by this pilot study, Philips and RealView Imaging will continue to explore the clinical value of combining live 3-D imaging and medical holography in interventional cardiology and other clinical areas.
 
For more information: www.philips.com, www.realviewimaging.com

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init